Work

Exendin-4 for Parkinson's disease

Year: 2021

Type: article

Abstract: This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeutic effects of the GLP receptor agonist exendin-4, also called exenatide, in PD. The ultimate goal of this article is to provide a critical assessment of the laboratory and clinical data toward guiding the translation of exendin-4 as a clinically relevant therapeutic for PD.

Source: Brain Circulation

DOI: 10.4103/bc.bc_21_21

Authors: Felipe de Jesús Esparza-Salazar, Alma Rosa Lezama-Toledo, Germán Rivera-Monroy, Cesario V. Borlongan

Institution: University of South Florida

Language: English

Topic: Parkinson's Disease Mechanisms and Treatments

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W3151452762

FWCI: 2.257

Cites: 21

Cited by: 23

Related to: 10